Compare Strategy Inc. (MSTR) vs Natera Inc. Common Stock (NTRA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Strategy Inc. vs Natera Inc. Common Stock — how do they compare? Strategy Inc. trades at $140.29 (market cap $64.44B), while Natera Inc. Common Stock trades at $394 (market cap $57.03B). The key difference: Strategy Inc. and Natera Inc. Common Stock are close in size by market cap, and Natera Inc. Common Stock is trading nearer its 52-week high, Strategy Inc. nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Strategy Inc. for 113 Days and Natera Inc. Common Stock for 0 Days on average.
| MSTR | NTRA | |
|---|---|---|
Market Cap | $64.44B | $57.03B |
Volume | 12,273,653 | 1,131,157 |
Sector | Technology | Health |
52-Week High | $301.91 | $425.64 |
52-Week Low | $82.31 | $179.42 |
Typical Hold Time | 113 Days | 0 Days |
Enterprise Value | $83.20B | $56.18B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MSTR stock trades at $143.24, down 6.18% today, with technical indicators showing neutral momentum near key support at $142. The company reported Q2 2026 EPS of -$24.45, missing expectations of -$2.19, continuing a trend of significant earnings misses. Despite negative profitability metrics including a -6,102.96% net income margin, analyst consensus remains bullish with 62% buy ratings and a $253.36 price target representing 77% upside potential from current levels.
The investment case hinges on analyst optimism despite fundamental challenges, with Citigroup recently doubling its price target to $240. Key risks include persistent negative earnings, high valuation multiples (P/S of 96.6), and substantial debt load of $7.19 billion. Cash flow trends show heavy reliance on financing activities to support operations and investments.
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Strategy Inc.
MicroStrategy Inc is a provider of enterprise analytics and mobility software. It offers MicroStrategy Analytics platform that delivers reports and dashboards and enables users to conduct ad hoc analysis and share insights through mobile devices or the Web
Read more on MSTR →About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →
